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Results must be interpreted with caution, and further studies are needed to carefully 
address limitations and improve upon these initial results.
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OBJECTIVES: Various factors may interact with Diabetes Mellitus (DM) to increase 
the risk of dementia. This study examined socio-demographic factors, the use of dia-
betes-speciﬁ c drugs and the duration of DM as risk factors for dementia in elderly
DM patients who are eligible to receive care at Veterans Health Administration.
METHODS: This was a retrospective study on a national cohort of US veterans. 
Incident DM elderly (q65 years) identiﬁ ed between October 1, 1996 and December 
31, 2000 in the VA records or between January 1, 1999 and December 31, 2000 in 
the VA-Medicare merged claims ﬁ les were included for the ﬁ nal analysis. The period 
prevalence of diabetes-speciﬁ c drugs was determined in Calendar Year (CY) 2000. The 
time to the incidence of dementia was assessed from CY2001 to CY2002. A multivari-
able Cox regression model was used to estimate the adjusted relative risk of dementia
for various predictors. RESULTS: A total of 377,838 patients were included in the
ﬁ nal analysis. Age was a major risk factor for dementia: patients 75–85 years of age, 
HR 2.09, 95% CI 2.02–2.17; patients 85 years and older, HR 3.47, 95% CI 3.27–
3.67. Compared to whites, African Americans had a higher risk of dementia (1.22,
1.16–1.27). People from the southern region of the U.S. had a higher risk of dementia 
compared to other regions. Oral hypoglycemic agent use was associated with a higher
risk of dementia (1.34, 1.29–1.39). The use of HMG-CoA reductase inhibitors was 
associated with a reduced risk of dementia (0.88, 0.85–0.91). Insulin was not associ-
ated with dementia (1.02, 0.98–1.07). The duration of diabetes was an important risk
factor for dementia. CONCLUSIONS: This exploratory study provides an important
insight into the risk factors for dementia in a large population of DM patients. Addi-
tional studies should examine the process and outcomes for patients with these 
important chronic disease conditions.
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OBJECTIVES: The aim of this study was to analyze trends and potential risks of 
combined use of silymarin and hypoglycemic drugs in a Taiwanese population. 
METHODS: Data for this retrospective and descriptive population-based study were
retrieved from the Taiwan National Health Insurance Research Database representing 
200,000 sampling beneﬁ ciaries enrolled in the program in the year 2000. The prescrip-
tion details of ambulatory care orders were retrieved for 2000 to 2006. The extent of 
co-prescription of silymarin and hypoglycemic drugs and associations with patient
characteristics, hospital type, and co-morbid chronic diseases were assessed, including 
an analysis using the many-faceted Rasch model. RESULTS: Silymarin prescriptions 
increased from 0.17% (860/515765) in 2000 to 0.76% (2335/309053) in 2006. Sily-
marin combined with hypoglycemic drugs was mostly prescribed to patients 60 years
or older. Among this group, the percentage of prescriptions with silymarin alone
increased about four-fold, from 245 in 2000 to 1022 in 2006. The number of co-pre-
scriptions in the same age group also increased in the same period from 11 (15.49%) 
to 206 (58.8%). Most prescriptions were prescribed for 28 days. Of the combined
prescriptions, 42% were prescribed at the same ambulatory care visit. Co-prescription
of silymarin and hypoglycemic drugs correlated with patient characteristics, physician
specialty, antidiabetic type, and other confounders. CONCLUSIONS: There was a
trend to increase of co-prescription of silymarin and hypoglycemic drugs in Taiwan’s 
elderly population from 2000 to 2006. Physicians should take particular care in 
adjusting the dose of hypoglycemic drugs when prescribing these drugs and silymarin 
concurrently in this age group.
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OBJECTIVES: To project the number of people with diagnosed diabetes in the United
States through 2025, accounting for changing demography and diabetes prevalence
rates. METHODS: We combined age, sex, and race speciﬁ c diabetes prevalence rates
– predicted from the 1980–1998 trends in prevalence data from the National Health 
Interview Survey – with the population projections derived from MEPS. Sensitivity 
analysis was performed by varying both population projections and prevalence rates.
RESULTS: Populations of the number of people with diabetes will rise to almost 18
million in 2025. The largest increases in the number of people with diabetes are likely 
to occur in the oldest age category. The highest growth will be among black males 
whereas the lowest increase will be in the white females category. Twenty percent of 
the overall projected growth will be due to population growth, 35% to an increase in 
prevalence rate, and 45% to changes in demographic compositions. CONCLUSIONS:
This paper shows the projection of dramatic increase of the diabetic population in the 
United States by 2025. Worldwide surveillance of diabetes is a necessary ﬁ rst step 
toward its prevention and control.
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OBJECTIVES: To examine utilization patterns and hypoglycemia in patients with
type-2 diabetes mellitus (T2DM) receiving concomitant exenatide and long-acting 
insulin therapy over 6 months. METHODS: A retrospective analysis was performed 
using claims data (January 1, 2004 to March 31, 2008) from a large US prescription 
database. Adult patients with T2DM and no claim for exenatide (index drug) in the
previous 12 months were included. At least 12 months pre-index and q6 months 
post-index continuous eligibility were required. Concomitant long-acting insulin use 
was deﬁ ned as a claim for NPH, insulin glargine or insulin detemir 100 days pre-index 
to 15 days post-index. Therapy discontinuation was deﬁ ned as a 60 day gap between 
prescription claims. Hypoglycemic events were identiﬁ ed by ICD-9 codes 250.8, 
251.0, 251.1, and 251.2. Hypoglycemia generating a claim using these codes is gener-
ally severe. RESULTS: Concomitant exenatide and long-acting insulin use was identi-
ﬁ ed in 2082 patients. Of these, 38% discontinued both therapies, 15% discontinued 
exenatide but remained on long-acting insulin, 24% discontinued long-acting insulin 
but remained on exenatide and 23% continued both therapies. There were no differ-
ences in age, gender or Deyo-Charleson comorbidity index score among cohorts.
Patients who discontinued exenatide and remained on long acting insulin had a higher 
mean rate of hypoglycemia (0.10 o 1.01 events/patient/6-months), compared to 
patients who discontinued long-acting insulin but remained on exenatide (0.02 o
0.20), discontinued both therapies (0.04 o 0.37) or continued both therapies (0.03 o
0.26; p  0.0001 across groups). Insufﬁ cient pre- and post-A1C values were available 
for an analysis of this endpoint. CONCLUSIONS: Patients remaining on concomitant
exenatide and long-acting insulin did not experience more hypoglycemic events than 
patients who remained on either drug alone. However, patients discontinuing exena-
tide but remaining on long-acting insulin experienced signiﬁ cantly more hypoglycemic 
events. The increase in hypoglycemic events may have been due to an increase in basal 
insulin dose and/or the addition of other insulin therapy.
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OBJECTIVES: Quantify the reductions in diabetic related complications associated 
with the addition of colesevelam hydrochloride to metformin in patients with type-2 
diabetes who have not achieved optimal control. METHODS: The quantiﬁ cation of 
the effects of pharmacologic intervention on glycaemic control in type-2 diabetics and
the quantiﬁ cation that improved glycaemic control reduces the risk of diabetic-related
complications was measured in the UK, Germany and the USA using Generalized
Estimating Equations (GEE) on longitudinal data. The three models quantiﬁ ed that 
pharmacologic intervention reduced HbA1c by 0.99%, 0.92% and 0.89%, respec-
tively, (P  0.01). The second set of models quantiﬁ ed that a 1% reduction in HbA1c 
reduced the rate of complications by 0.388%, 0.414% and 0.436% (P  0.01). Using
these validated equations, the efﬁ cacy data from a clinical trial comparing the addition
of colesevelam hydrochloride to metformin versus metformin alone in type 2 diabetic 
patients who lack optimal control despite treatment was converted into reductions in
the onset new diabetic-related complications. 5000 bootstrap samples of 100 patients 
from each treatment group were replicated to measure and minimize bias. RESULTS:
In the ﬁ rst year, the addition of colesevelam to metformin reduces the number of dia-
betic related complications by 10,757 in 100,000 type-2 diabetics who lack glycaemic 
control despite treatment. The most prevalent of those complications are manifesta-
tions of neurological dysfunction (0.0166), disorders of the peripheral circulation
(0.0170) and ischemic heart disease (0.0178). Treatment with coleselevam in these 
patients who had not achieved optimal control reduced those events by 1790 neuro-
logical disorders, 1829 peripheral circulatory disorders and 1917 new cases of isch-
emic heart disease. The number of events avoided by year two and three accrued to 
18,173 and 27,505 per 100,000 patients. CONCLUSIONS: Effective treatment by 
adding colesevelam to metformin quantiﬁ ably reduces HbA1c and complications in 
patients who have not achieved control.
